Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia
Martin Bornhäuser(Technische Universität Dresden), Gerhard Ehninger(University Hospital Carl Gustav Carus), Markus Schaich(Rems-Murr-Klinikum), Uta Oelschlaegel(University Hospital Carl Gustav Carus), Alexander Kiani(Bayreuth Medical Center), Thomas Illmer(Center for Systems Biology Dresden), Ulrich S. Schuler(University Hospital Carl Gustav Carus), Mathias Hänel(Klinikum Chemnitz), Rainer Ordemann, Johannes Schetelig(University Hospital Carl Gustav Carus), Uwe Platzbecker(National Center for Tumor Diseases), Christian Thiede(University Hospital Carl Gustav Carus)
Cited by 26
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k